● TIER 3 — Information onlyGRADE BGLP-1 / incretins & amylin
Survodutide
Glucagon/GLP-1 dual agonist. Research verification: Yes (TGA pending). 1 human study record(s) in the FitClinicMD studies database.
GOALS · Weight loss
FDA status
Phase 3 (SYNCHRONIZE) — not FDA-approved.
Compounding (503A/503B)
Not compoundable.
DEA
Not controlled.
WADA (sport)
S0 Non-approved substances
Mechanism
Glucagon/GLP-1 dual agonist.
Human evidence · 1
Peer-reviewed trial. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
Reference only. This page summarizes publicly available regulatory and research information about Survodutide. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.